Roche and Biogen Idec suspend RA trials with ocrelizumab

Monday 8 March 2010

The Roche Group and Biogen Idec of the US have suspended clinical trials of the humanized anti-CD20 monoclonal antibody, ocrelizumab, in four rheumatoid arthritis trials because of safety issues. The drug was in Phase 2 and 3 trials.

 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland